SCHEMBL20898650

SCHEMBL20898650

CC1(C)C[C@H]2CN(c3ccccc3)[C@@H]1CNC2=O

nearest known ligand 0.38

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.38
G6PD P11413 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
ALOX5 P09917 3/20 0.35
DDB1 Q16531 2/20 0.33
CRBN Q96SW2 2/20 0.33
ADAMTS5 Q9UNA0 1/20 0.32
SLC6A9 P48067 1/20 0.32
HSD17B10 Q99714 2/20 0.32
KDM4E B2RXH2 1/20 0.32
ALDH1A1 P00352 1/20 0.32
HPGD P15428 1/20 0.32
OPRM1 P35372 1/20 0.32
OPRD1 P41143 1/20 0.32
OPRK1 P41145 1/20 0.32
OPRL1 P41146 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22567582 1.00 GAA (0.38) GAAG6PDL3MBTL1ALOX5DDB1
SCHEMBL22567323 0.86 ADAMTS5 (0.34) DDB1CRBNADAMTS5ALDH1A1
SCHEMBL22555807 0.86 ADAMTS5 (0.34) DDB1CRBNADAMTS5ALDH1A1
SCHEMBL22555747 0.84 GAA (0.40) GAAL3MBTL1DDB1CRBNALDH1A1
SCHEMBL20898255 0.82 PDE3B (0.38) GAAL3MBTL1HSD17B10KDM4EALDH1A1
SCHEMBL22555783 0.81 LMNA (0.40) GAAL3MBTL1ALDH1A1HPGD
SCHEMBL22567300 0.81 LMNA (0.40) GAAL3MBTL1ALDH1A1HPGD
SCHEMBL22555768 0.81 LMNA (0.40) GAAL3MBTL1ALDH1A1HPGD
SCHEMBL29616666 0.81 MEN1 (0.44) GAAL3MBTL1DDB1CRBNHSD17B10
SCHEMBL22567593 0.78 ALDH1A1 (0.36) GAAG6PDL3MBTL1ALOX5DDB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12060360-B2 Lysyl oxidase inhibitors THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) 2024-08-13 US disclosed
US-20220289757-A1 LYSYL OXIDASE INHIBITORS THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) 2022-09-15 US disclosed
US-11325915-B2 Lysyl oxidase inhibitors THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) 2022-05-10 US disclosed
US-11325915-B2 Lysyl oxidase inhibitors THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) 2022-05-10 US disclosed
US-20200331922-A1 LYSYL OXIDASE INHIBITORS THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) 2020-10-22 US disclosed
US-20200331922-A1 LYSYL OXIDASE INHIBITORS THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) 2020-10-22 US disclosed
EP-3694857-A1 LYSYL OXIDASE INHIBITORS The Institute of Cancer Research: Royal Cancer Hospital (GB) 2020-08-19 EP disclosed
WO-2019073251-A1 LYSYL OXIDASE INHIBITORS THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) 2019-04-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200331922-A1 LYSYL OXIDASE INHIBITORS LOXL1, LOXL2, LOXL3 GAA 437/4885G6PD 2693/4885L3MBTL1 312/4885
US-12060360-B2 Lysyl oxidase inhibitors LOXL1, LOXL2, LOXL3 GAA 437/4885G6PD 2693/4885L3MBTL1 312/4885
US-20220289757-A1 LYSYL OXIDASE INHIBITORS LOXL1, LOXL2, LOXL3 GAA 437/4885G6PD 2693/4885L3MBTL1 312/4885
US-11325915-B2 Lysyl oxidase inhibitors LOXL1, LOXL2, LOXL3 GAA 437/4885G6PD 2693/4885L3MBTL1 312/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.